The United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia."

The newly issued patent is expected to provide U.S. intellectual property protection for Nexalin's core dynamic frequency stimulation method through 2042, further strengthening the Company's long-term competitive position in frequency-based deep-brain neurostimulation for anxiety, depression and insomnia.